Home  :  Product Search  :  Site Map  :  Checkout  :  Track Your Order
GenJet™ In Vitro DNA Tranfection Reagent for LNCaP Cells
Search by Keyword

Search by Keyword

Product Categories

Product Categories

Description

GenJet™ DNA In Vitro Tranfection Reagent for LNCap is pre-optimized for transfecting LNCap cells. LNCap cells are a cell line of human cells commonly used in the field of oncology. LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old caucasian male in 1977. They are adherent epithelial cells growing in aggregates and as single cells.

Refer to the following optimal transfection conditions for maximal transfection efficiency on LNCap cells. GenJet™ reagent, 1.0 ml, is sufficient for 300 to 600 transfections in 24 well plates or 50 to 100 transfections in 6 well plates.

Summary of Optimal Transfection Conditions:
Confluence on the day of transfection
Cell culture conditions
GenJet™ (µl) : DNA (µg) Ratio
Diluent for DNA and Transfection Reagent

Incubation Time to Form GenJet™/DNA Complex
Presence of Serum/Antibiotics during Transfection
Change Medium After Transfection
Maximal Efficiency 


Transfection Results:
Reporter Gene
Plasmid
Efficiency (GFP %)


95%
DMEM with 4.5 g/L glucose, 10% FBS

3:1
Serum-free DMEM with 4.5 g/L glucose

15 minutes at RT
Yes
No
48 hours


EGFP
pEGFP-N3 (CMV promoter) 

80%

Storage Condition
Store at 4 °C. If stored properly, the product is stable for 12 months or longer


GenJet™ reagent is optimized for LNCap cells. LNCap cells were grown per ATCC recommended culture medium and transfected with pEGFP-N3 by GenJet™ (Ver. II). The efficiency was checked 48 hours post transfection 
Data Sheet 


Copyright © egfie Herndon, VA
customer@egfie.com